Biocon Biologics is planning to raise $950 million through overseas bonds

September 14, 2024

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.’s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond’s rating will determine its pricing.

More To Explore

Stocks to Buy | 2 top stock recommendations from Aditya Arora

Markets are showing impressive performance with FMCG and Metal sectors leading the way. Aditya Arora of Adlytick highlights Hindustan Unilever and Emami as promising stocks

March 10, 2025

HCL Technologies, Crisil among 10 stocks with up to 64 dividend payouts since 2011

A dividend is a share of profits and retained earnings that a company pays out to its shareholders. According to StockEdge data, 10 stocks have

March 10, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003